Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07174986

Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest

Some of the patients affected by Out-of-hospital cardiac arrest (OHCA) with ventricular fibrillation (VF)/ventricular tachycardia (VT) do not respond to initial defibrillation. The survival decreases with number of defibrillations required to terminate VF/VT. In 2022, one prospective cluster randomized trial showed increased survival among (OHCA) patients in refractory VF using Double Sequential Defibrillation (DSD). If DSD can increase survival among all patients in VF that dont respond to one defibrillation, i.e. before it has become refractory is not known.

The aim of this trial is to assess survival with a double defibrillation strategy initiated as soon as possible among patients with Out of Hospital Cardiac Arrest with initial shockable rhythm and at least one failed standard defibrillation, compared with continued resuscitation using standard defibrillation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

ARREST (AmsteRdam REsuscitation STudies), Amsterdam, Netherlands

Loading trial locations.

About this study

Background: Out-of-hospital cardiac arrest (OHCA) affects about 270,000 individuals in Europe annually.[1] In OHCA, presenting with ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) amendable to defibrillation are among the strongest predictors of survival.[2] If defibrillation can be done successfully within the first 3-5 minutes survival can be as high as 70 %.[3] However, some patients in VT/VF do not respond to initial defibrillation, and survival decreases with number of defibrillations required to terminate VT/VF.[4]

In 2022, one prospective cluster randomized trial showed increased survival among OHCA patients in refractory VF using an alternative defibrillation strategy with either, switching to Anterior-Posterior defibrillation pad placements (A-P) or Double Sequential Defibrillation "DSD", (Using two defibrillators, one in the standard anterior-lateral position (A-L) and one in A-P position and defibrillation in rapid sequence) compared to standard defibrillation pad placement.[5] Refractory VF was defined as VF that persisted despite three consecutive defibrillations with defibrillation pads in the standard position.

These results prompted the International Liaison Committee on Resuscitation (ILCOR) to release a statement of treatment recommendation on DSD in March 6, 2023. It suggested that "…either vector change or DSD may be considered for adults with cardiac arrest who remain in VF or pulseless VT despite three defibrillations (weak recommendation, low certainty of evidence)." [6] Further, if DSD would be used it should be performed with a methodology similar to that described in the trial by Cheskes et al.

However, several questions remain. Knowledge gaps highlighted in the ILCOR statement included if the results from this one cluster randomized trial could be reproduced in any other setting. Further, since survival is inversely associated with the number of defibrillation shocks, if earlier application of DSD could lead to even higher survival for patients not in refractory VF has never been studied.

Study rationale: In order to evaluate if an early DSD-strategy could benefit all patients with VT/VF after the first shock, including those not in refractory VF, the Double-D trial is designed. If DSD would prove to be superior to standard defibrillation in a broader cardiac arrest population, also among those not in refractory VF, this would have a large impact on how Advanced Cardiac Life Support (ACLS) should be performed.

Design: This is an academic, investigator initiated, open-label pilot study with a randomized controlled trial (RCT) design and 1:1 allocation (1 DSD: 1 standard). Screening for inclusion will be performed in all cardiac arrests by participating EMS units where there are two study-specific defibrillators available on site.

Study population: Adult OHCA patients with pulseless VT/VF at initial rhythm analysis, at least one defibrillation performed in standard A-L position without return of spontaneous circulation (ROSC).

P: Adult patients, 18 years or older, with OHCA, initial shockable rhythm (VT/VF) and, at least, one defibrillation performed in standard position and ongoing CPR (no ROSC).

I: Application of a second defibrillator with pad-placement in the anterior-posterior (A-P) position as early as possible after the first shock and double sequential defibrillation after the following rhythm analysis if the patient is still in VT/VF.

C: Standard defibrillation electrode placement (A-L) and routine defibrillation with one defibrillator after the following rhythm analysis if the patient is still in VT/VF.

O: Primary outcome is 30-day survival.

The trial will be conducted by participating ambulance units attending OHCA´s. These units will perform screening for inclusion, randomization, intervention or control treatment and initial follow up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • OHCA patients with VT/VF at first rhythm analysis and at least one defibrillation performed in standard (A-L) position

Exclusion criteria

  • Age < 18 years
  • Obvious pregnancy
  • Known preexisting Do Not Attempt Resuscitation order

Treatment and study plan

Double sequential defibirllation

Device

A second defibrillator will be applyed with electrodes placed in the A-P position and defibrillation will be performed with two defibrllators in a sequential manner

Other names: DSD

Standard defibrillation

Device

Standard defibrillation uning one defibrillator

Primary outcomes

  1. 30 day survival

    Time frame: 30 days

    Survival at 30 days

Secondary outcomes

  1. ROSC

    Time frame: 1 day

    Any prehospital ROSC, defined as confirmed ROSC by EMS personnel, in accordance with latest Utstein definition

  2. Survival to hospital Admission

    Time frame: 1 day

    Admitted alive to a hospital ward with spontaneous circulation

  3. Survival to hospital discharge

    Time frame: 30 days

    Discharged alive from hospital

  4. Neurological function at hospital discharge, mRS (modified Ranking scale, 1-6 where 1 indicates better function)

    Time frame: 30 days

    Neurological function at hospital discharge (mRS)

Other outcomes

  1. 90 days survival

    Time frame: 90 days

    Survival to 90 days

  2. Neurological function at 90 days (mRS)

    Time frame: 90 days

    Neurological function at 90 days (modified Ranking scale)

  3. Helath related quality of life at 90 days

    Time frame: 90 days

    Helath related quality of life at 90 days

  4. Neurological function at 180 days (mRS)

    Time frame: 180 days

    Neurological function (modified Ranking Scale)

  5. Health related quality of life at 180 days

    Time frame: 180 days

    Health related quality of life at 180 days

  6. Number of defibrillations to sustained ROSC

    Time frame: 1 day

    Total number of defibrillations to sustained ROSC

  7. Termination of ventricular fibrillation

    Time frame: 1 day

    defined as the presence as a non-shockable rhythm 5 seconds after defibrillation

Study contacts

Contact information is provided by the study sponsor or research team.

Akil Awad, M.D. Ph.D.

CONTACT

[email protected]

(+46) 070 400 13 63

Gabriel Riva, M.D. Ph.D

CONTACT

[email protected]

+ 47 70 545 20 86

Sponsors and collaborators

Lead sponsor

Gabriel Riva

Other

Collaborators

  • Laerdal Foundation
  • Region Halland
  • Region Stockholm
  • Swedish Heart Lung Foundation
  • Vastra Gotaland Region

Registry information

Official study title

"A Randomized Trial Assessing the Effect of Early Double Sequential Defibrillation With Anterior-posterior and Anterior Lateral Pad Placement and Sequential Defibrillation Compared to Standard Pad Placement and Single Defibrillation in Patients With Out of Hospital Cardiac Arrest With Initial Shockable Rhythm and at Least One Failed Standard Defibrillation"

Acronym: DOUBLE D

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Sep 16, 2025
Registry last updated
Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.